Trials / Completed
CompletedNCT00550381
Study Evaluating the Safety, Tolerability, and Pharmacokinetics (PK) of HKI-357 Administered Orally to Healthy Subjects
Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of HKI-357 Administered Orally to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of single doses of HKI-357 administered to healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HKI-357 | Single-dose capsule |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-03-01
- Completion
- 2008-03-01
- First posted
- 2007-10-29
- Last updated
- 2009-07-10
Source: ClinicalTrials.gov record NCT00550381. Inclusion in this directory is not an endorsement.